News About: Pharm. Industry
Hanmi reveals total 23 pipelines consisting of 14 biologics and 9 synthesized drugsHanmi Pharm(CEO Sae-Chang Kwon & Jong-Soo Woo) revealed the development status(hereinafter referring to pipeline) of 23 new drugs which are currently being developed now in 2017...
|
‘Top 5’ listed pharmas in R&D ratio to sales were ISU Abxis, Celltrion, Hanmi, Bukwang, Pharmicell
It was observed KOSDAQ listed pharmaceutical companies recorded a 3-times higher average growth rate of R&D expenses than the one in the KOSPI. When it comes to its ratio to sales, KOSDAQ listed pharmaceutical compani...
Will rebates impact selection of innovative pharmaceutical company?
Rebates have brought influences on revoking innovative pharmaceutical companies.
According to a source from the industry concerned, the company A got revoked as innovative pharmaceutical company for suspension of bus...
Korea’s largest place for ‘technology transfers’ will open for pharma & bio industries
The ‘15th Interbiz Bio-Partnering & Investment Forum 2017(hereinafter referring to ‘Interbiz Forum’),’ the Korea’s largest place for technology transfers to generate new market values and secure innovation and product...
Listed pharmas’ annual employee benefits per employee were KRW 6.67 million
It was observed listed pharmaceutical company employees receive employee benefits of approximately KRW 6.67 million last year. In addition, 7 pharmaceutical companies including Daehan New Pharm and Myungmoon Pharm rec...
KOSPI records a merchandise sales/sales ratio twice larger than one of KOSDAQ
It was observed the KOSPI listed pharmaceutical companies’ merchandise sales growth rate was much higher than the one of the KOSDAQ. In terms of the merchandise sales ratio to sales, KOSDAQ listed drug companies had a...
Listed pharmas pay KRW 53 million per employee annually
The listed pharmaceutical companies’ average annual salary was KRW 53 million, and Dong-A Socio Holdings recorded the highest KRW 83 million.
In addition, the average annual salary for men was KRW 58.56 million, but ...
Growth rate of export was 20% in KOSDAQ, but negative in KOSPI
While pharmaceutical companies in the KOSDAQ showed a large growth in overseas sales & export on average compared to the year before, KOSPI listed pharmaceutical companies recorded a negative value in the growth ratio...
Pharma industry, “There is a limit in ETC, and we are gaining growth engine back with OTC”
28% of pharmaceutical products approved in the 1st quarter was observed to be OTC drugs, which brings an analysis that pharmaceutical companies are active in developing OTC drugs.
According to the Ministry of Food an...
Listed pharmas make KRW 400 million annual sales per employee a year
Listed pharmaceutical companies made KRW 400 million annual sales per employee on average last year, and Kwang Dong Pharmaceutical recorded the highest KRW 1.06 billion.
Moreover, companies which made the highest ann...
